Researchers at Systems Biology Ireland (SBI), University College Dublin, have developed a novel approach to understand the distinction between pathological and healthy states of human cells. Their findings were published in Nature today.
The cells in the human body have a remarkable ability to change. Normally, this ability is used to replenish or repair tissues. However, in diseases such as cancer, cells can adopt states that harm the body. SBI researchers have now developed a method, cell state transition assessment and regulation (cSTAR), which can distinguish healthy and diseased cell states using molecular data, and identify the key molecules that characterise the different states. By revealing the underlying decision-making process, cSTAR also informs scientists how to purposefully change cell states using targeted manipulations, e.g. specific drugs.
“In this paper, we have built on the fundamental work of SBI researchers to understand cellular gene and protein networks that control the life of cells,” said Professor Boris Kholodenko, lead author on the study, and SFI Stokes Professor of Systems Biology at Systems Biology Ireland and UCD Conway Institute.
"Like many leading laboratories in the world, we have a long-standing interest in understanding how to control the cell states or fates. Where our work differs is in its use of machine learning, advanced computational and physical approaches and models with the ultimate goal of creating digital twins to precisely model human diseases and targeted interventions to cure these diseases.” Professor Kholodenko is ranked World #1 in Computational and Mathematical Modelling.*
Professor Walter Kolch, Director of SBI and co-author, said, “Controlling cell state transitions is a holy grail in biology and biomedicine. Being able to design and exert such control reliably and with precision opens many doors.”
A leading international proponent of precision medicine, Kolch continued, “For instance, we could force cancer cells to stop growing and spreading; we could accelerate cell differentiation to repair tissues more efficiently; we could prevent cells from premature death in degenerative diseases, and so on. Like the invention of the microchip allowed us to design a range of smart tools that control our car, microwave, phone and heating, cSTAR is a universal tool that will allow us to control cell states for biomedical benefit.”
The team at SBI are currently deploying and honing cSTAR for addressing major challenges in human diseases. One focus is cancer, where they believe that cSTAR will help to design more effective drug combinations that can be personalised to individual patients using digital twin models. Another focus for the future is infectious diseases, such as tuberculosis.
Since 2009, SBI investigators have published more than 495 research and review articles in journals. Over this same period, the group has identified and validated numerous new and promising therapeutic targets for treatment of breast cancer, melanoma, neuroblastoma, and colorectal cancer.
The new paper ‘Control of cell state transitions’ is available here: https://www.nature.com/articles/s41586-022-05194-y
*Google Scholar Oct 2021